Tibet Aim Pharm Inc Working Capital to Net Assets Ratio
Tibet Aim Pharm Inc working capital to net assets ratio. Tibet Aim Pharm Inc (002826) has a Working Capital to Net Assets ratio of 55.2% as of March 2026. Working capital of CN¥462.81 Million (current assets of CN¥723.27 Million minus current liabilities of CN¥260.46 Million) is measured against net assets of CN¥838.02 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Tibet Aim Pharm Inc's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Tibet Aim Pharm Inc (2013–2025)
Working capital to net assets ratio of Tibet Aim Pharm Inc from 2013 to 2025. This chart shows how Tibet Aim Pharm Inc's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 55.2%, reflecting working capital of CN¥462.81 Million against net assets of CN¥838.02 Million CNY. See Tibet Aim Pharm Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Tibet Aim Pharm Inc Working Capital to Net Assets Ratio by Year (2013–2025)
Tibet Aim Pharm Inc working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Tibet Aim Pharm Inc from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Tibet Aim Pharm Inc assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 53.6% | CN¥437.00 Million | CN¥816.02 Million | CN¥633.68 Million | CN¥196.68 Million | ▲ +6.3 pp |
| 2024 | 47.3% | CN¥352.50 Million | CN¥745.58 Million | CN¥527.61 Million | CN¥175.12 Million | ▲ +4.8 pp |
| 2023 | 42.5% | CN¥318.59 Million | CN¥750.06 Million | CN¥489.67 Million | CN¥171.08 Million | ▲ +0.7 pp |
| 2022 | 41.7% | CN¥313.10 Million | CN¥750.00 Million | CN¥575.01 Million | CN¥261.91 Million | ▲ +5.2 pp |
| 2021 | 36.5% | CN¥262.83 Million | CN¥720.11 Million | CN¥362.17 Million | CN¥99.35 Million | ▲ +2.7 pp |
| 2020 | 33.8% | CN¥231.98 Million | CN¥687.15 Million | CN¥450.25 Million | CN¥218.27 Million | ▼ 0.0 pp |
| 2019 | 33.8% | CN¥220.26 Million | CN¥652.17 Million | CN¥400.57 Million | CN¥180.30 Million | ▼ -19.0 pp |
| 2018 | 52.8% | CN¥326.56 Million | CN¥618.40 Million | CN¥464.22 Million | CN¥137.66 Million | ▼ -5.7 pp |
| 2017 | 58.5% | CN¥353.42 Million | CN¥604.53 Million | CN¥479.56 Million | CN¥126.14 Million | ▼ -6.9 pp |
| 2016 | 65.4% | CN¥363.12 Million | CN¥555.44 Million | CN¥452.01 Million | CN¥88.90 Million | ▲ +24.7 pp |
| 2015 | 40.6% | CN¥100.90 Million | CN¥248.25 Million | CN¥208.40 Million | CN¥107.49 Million | ▲ +1.2 pp |
| 2014 | 39.5% | CN¥70.68 Million | CN¥179.12 Million | CN¥159.72 Million | CN¥89.05 Million | ▲ +44.1 pp |
| 2013 | -4.6% | CN¥-3.30 Million | CN¥71.66 Million | CN¥78.14 Million | CN¥81.43 Million | — |